Gene · 79679
Papers2,409
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
381 to 400 of 2,409
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer. | Mol Cancer Ther | 2023 | 37294948 | PubTator, text mining | PubMed |
| Development and Validation of the Promising PPAR Signaling Pathway-Based Prognostic Prediction Model in Uterine Cervical Cancer. | PPAR Res | 2023 | 37292383 | PubTator, text mining | PubMed |
| Identification of colorectal cancer progression-associated intestinal microbiome and predictive signature construction. | J Transl Med | 2023 | 37291572 | PubTator, text mining | PubMed |
| The potential of FCRL genes as targets for cancer treatment: insights from bioinformatics and immunology. | Aging (Albany NY) | 2023 | 37285836 | PubTator, text mining | PubMed |
| Non-oncology drug (meticrane) shows anti-cancer ability in synergy with epigenetic inhibitors and appears to be involved passively in targeting cancer cells. | Front Oncol | 2023 | 37274234 | PubTator, text mining | PubMed |
| The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneity. | Front Oncol | 2023 | 37265795 | PubTator, text mining | PubMed |
| TMIGD2 as a potential therapeutic target in glioma patients. | Front Immunol | 2023 | 37261362 | PubTator, text mining | PubMed |
| An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity. | Cell Mol Biol Lett | 2023 | 37259060 | PubTator, text mining | PubMed |
| Risk prediction for dermatomyositis-associated hepatocellular carcinoma. | BMC Bioinformatics | 2023 | 37259059 | PubTator, text mining | PubMed |
| Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors. | Clin Cancer Res | 2023 | 37256648 | PubTator, text mining | PubMed |
| Dynamic polarization of tumor-associated macrophages and their interaction with intratumoral T cells in an inflamed tumor microenvironment: from mechanistic insights to therapeutic opportunities. | Front Immunol | 2023 | 37251409 | PubTator, text mining | PubMed |
| Identification of intestinal microbiome associated with lymph-vascular invasion in colorectal cancer patients and predictive label construction. | Front Cell Infect Microbiol | 2023 | 37249979 | PubTator, text mining | PubMed |
| Butyrophilins: Dynamic Regulators of Protective T Cell Immunity in Cancer. | Int J Mol Sci | 2023 | 37240071 | PubTator, text mining | PubMed |
| The Role of Peroxiredoxins in Cancer Development. | Biology (Basel) | 2023 | 37237480 | PubTator, text mining | PubMed |
| Bioinformatics and network biology approach to identifying type 2 diabetes genes and pathways that influence the progression of breast cancer. | Heliyon | 2023 | 37234659 | PubTator, text mining | PubMed |
| Circular RNA circEIF3C promotes intrahepatic cholangiocarcinoma progression and immune evasion via the miR-34a-5p/B7-H4 axis. | Genes Dis | 2023 | 37223528 | PubTator, text mining | PubMed |
| Cuproptosis combines immune landscape providing prognostic biomarker in head and neck squamous carcinoma. | Heliyon | 2023 | 37215927 | PubTator, text mining | PubMed |
| Roles of glycosylation at the cancer cell surface: opportunities for large scale glycoproteomics. | Theranostics | 2023 | 37215580 | PubTator, text mining | PubMed |
| New insights and options into the mechanisms and effects of combined targeted therapy and immunotherapy in prostate cancer. | Mol Ther Oncolytics | 2023 | 37215386 | PubTator, text mining | PubMed |
| Macrophages in immunoregulation and therapeutics. | Signal Transduct Target Ther | 2023 | 37211559 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/79679/papers?page=20